{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Fulgent Genetics, Inc.
Is Fulgent Genetics, Inc. technically bullish or bearish?
As of October 31, 2025, Fulgent Genetics, Inc. shows a mildly bullish trend with positive momentum indicators, but has underperformed the S&P 500 over the past year and longer, reflecting mixed signals and historical weakness.
Fulgent Genetics, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Fulgent Genetics, Inc. has recently revised its evaluation amid current market conditions. The stock price has seen a slight increase, with a year-to-date return surpassing the S&P 500. However, its longer-term performance remains below the broader market, reflecting ongoing challenges within the company and industry.
Is Fulgent Genetics, Inc. technically bullish or bearish?
As of October 31, 2025, Fulgent Genetics, Inc. shows a mildly bullish technical trend with positive momentum indicators, but it has underperformed the S&P 500 over the long term despite a year-to-date outperformance.
Is Fulgent Genetics, Inc. technically bullish or bearish?
As of October 31, 2025, Fulgent Genetics, Inc. has a mildly bullish technical trend, with positive indicators like MACD and KST, despite recent underperformance against the S&P 500 over the past month and week, while still outperforming year-to-date.
Is Fulgent Genetics, Inc. technically bullish or bearish?
As of October 31, 2025, Fulgent Genetics, Inc. shows a mildly bullish technical trend with positive indicators, despite underperforming the S&P 500 recently, while year-to-date performance remains strong.
Fulgent Genetics Hits New 52-Week High at $23.57
Fulgent Genetics, Inc. has achieved a new 52-week high, reflecting a year-over-year performance increase. With a market capitalization of USD 682 million, the company faces challenges, including a negative return on equity and no dividend yield, as it navigates the competitive biotechnology sector.
Is Fulgent Genetics, Inc. technically bullish or bearish?
As of September 12, 2025, Fulgent Genetics, Inc. shows a mildly bullish trend with positive indicators from MACD and Bollinger Bands, despite mixed signals from KST and OBV, while outperforming the S&P 500 in the short term but underperforming over the longer term.
Is Fulgent Genetics, Inc. overvalued or undervalued?
As of May 5, 2023, Fulgent Genetics, Inc. is considered risky and overvalued due to negative earnings metrics and low valuation ratios, with significantly worse financial metrics compared to peers like Ginkgo Bioworks, indicating challenges in profitability and market performance.
Fulgent Genetics Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators
Fulgent Genetics, Inc. has experienced stock price fluctuations, with a recent trading range between $21.49 and $22.07. Technical indicators present a mixed outlook, showing both bullish and bearish signals. Over the past year, the stock has declined slightly, yet it has outperformed the S&P 500 year-to-date.
Is Fulgent Genetics, Inc. overvalued or undervalued?
As of May 5, 2023, Fulgent Genetics, Inc. is considered overvalued with a risky valuation grade, reflected in its negative P/E ratio of -19.40 and poor stock performance, lagging behind the S&P 500 with a 1-year return of -4.64%.
Is Fulgent Genetics, Inc. technically bullish or bearish?
As of June 17, 2025, Fulgent Genetics, Inc. shows a mildly bullish trend supported by a bullish MACD on the weekly chart, but mixed signals from monthly Bollinger Bands and Dow Theory suggest a cautious outlook.
Who are in the management team of Fulgent Genetics, Inc.?
As of March 2022, the management team of Fulgent Genetics, Inc. includes Mr. Ming Hsieh as Chairman, President, and CEO, along with independent directors Mr. John Bolger, Ms. Linda Marsh, and Dr. Yun Yen.
What does Fulgent Genetics, Inc. do?
Fulgent Genetics, Inc. is a biotechnology company that provides genetic testing for clinically actionable diagnostic information to enhance patient care. As of March 2025, it reported net sales of $73 million and a net loss of $12 million, with a market cap of $616.79 million.
How big is Fulgent Genetics, Inc.?
As of Jun 18, Fulgent Genetics, Inc. has a market capitalization of 616.79 million and reported net sales of 292.44 million with a net profit of -41.87 million over the latest four quarters. Shareholder's funds are 1,133.23 million, and total assets amount to 1,257.08 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
